Up next

Supplier News: CordenPharma, Curia, Sartorius & More 

The latest from CDMOs, CMOs, and suppliers featuring CordenPharma, Curia, Sartorius, Niowave, Asahi Kasei, WuXi Biologics, GBI Manufacturing and Scinai Biopharma Services.  

Chemicals/Chemical API Manufacturing 
* CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity  
* Curia Upgrades API Aseptic Suites
* Niowave Breaks Ground on $75-M Radioisotope Mfg Facility 
Biologics Manufacturing 
* Sartorius Opens New Center To Support Cell & Gene Therapies 
* Asahi Kasei Life Science Acquires License for ADC Technology
Formulation Development/Drug Product Manufacturing 
* WuXi Biologics Achieves GMP Release for Drug-Product Mfg Facility 
Appointments 
* GBI Manufacturing Appoints Chief Business Officer 
* Scinai Biopharma Services Names Head of CDMO Facility 

Chemicals/Chemical API Manufacturing 

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity 
CordenPharma, a CDMO of drug substances and drug products, has agreed to acquire AmbioPharm, a North Augusta, South Carolina-based CDMO specializing in peptide-based active pharmaceutical ingredients (APIs).  

AmbioPharm employs approximately 400 people across its two sites, one in North Augusta, South Carolina, and one in Shanghai, China, and the acquisition adds differentiated peptide manufacturing capabilities to CordenPharma’s existing peptides platform and expertise. Once combined, these will include advanced linear and fragment-based peptide approaches supported by solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid synthesis, as well as CordenPharma’s tag-assisted peptide synthesis.  

AmbioPharm’s South Carolina, site will add capacity for purification and lyophilization of peptide APIs and will complement CordenPharma’s existing capabilities at its site in Colorado. AmbioPharm’s Shanghai site will support clinical and commercial global peptide supply with upstream capacity across SPPS, LPPS, and hybrid synthesis, as well as selected downstream capabilities. 

Source: CordenPharma 

Curia Upgrades API Aseptic Suites 
Curia, a CDMO of drug substances and drug products, has completed a $4-million investment to upgrade its two active pharmaceutical ingredient (API) aseptic suites in Valladolid, Spain. 

The central feature of the upgrade was the transition to a fully closed system to strengthen process and product integrity while minimizing microbiological risk across all stages of production. Enhancements also focused on modernizing core equipment and systems, including the installation of advanced isolators, as well as upgrades to HVAC, pharmaceutical utilities, automation and sterilization-in-place processes. 

Source: Curia 

Niowave Breaks Ground on $75-M Radioisotope Mfg Facility 
Niowave, a Lansing, Michigan-based CDMO, has broken ground on a new $75-million production facility in Lansing, Michigan, to strengthen its domestic supply of Actinium‑225 (Ac‑225), an isotope used in targeted cancer therapies. The new site, Niowave’s second dedicated production facility in Lansing, will increase capacity to support growing global demand for Ac-225 and other medical isotopes. The site is expected to become operational in 2028. 

Source: Niowave 

Biologics Manufacturing 

Sartorius Opens New Center To Support Cell & Gene Therapies 
Sartorius, a provider of products and services for the life-sciences industry, including bioprocessing, has opened a new EUR 140-million ($163-million) competence center in Freiburg, Germany, to support the development and production of cell and gene therapies. In Freiburg, the company manufactures components such as cytokines and growth factors used in these therapies.  

Source: Sartorius 

Asahi Kasei Life Science Acquires License for ADC Technology 
Asahi Kasei Life Science, a provider of biopharmaceutical purification and bioprocessing technologies and CDMO services, has acquired the license rights for an antibody-drug conjugate (ADC) technology from the Noguchi Institute, a research institute. Drawing on research into carbohydrates and glycans, the technology is designed to enable control over the drug-to-antibody ratio and attachment site of single- and dual-payload ADCs.  

Under the agreement, the two partners will advance initiatives to commercialize ADC drug platforms, including possible future sub-licensing to biopharma companies and CDMOs, such as Bionova Scientific, an Asahi Kasei company. In addition, both parties will engage in joint research to further refine the technology. 

Source: Asahi Kasei 

Lonza, Oxford Nanopore Technologies Launch Tool for QC Testing for mRNA Therapeutics 
Lonza and Oxford Nanopore Technologies, a company focused on nanopore-based molecular sensing technology, have announced the launch of a new technology approach for GMP quality control testing for mRNA therapeutics. The technology combines direct RNA sequencing using nanopore technology with machine learning-based data analysis and customized software.  

Source: Oxford Nanopore Technologies 

Formulation Development/Drug Product Manufacturing 

WuXi Biologics Achieves GMP Release for Drug-Product Mfg Facility 
WuXi Biologics, a CDMO of biologics and drug products, has announced that its drug-product facility (aseptic filling for liquid and lyophilized drug products) in Fengxian, Shanghai, China, achieved GMP release in April 2026. The facility is the eighteenth operational drug-product facility in the company’s global network. 

Source: WuXi Biologics 

Appointments 

GBI Manufacturing Appoints Chief Business Officer 
GBI Biomanufacturing, a biologics CDMO, has appointed Chandra Kelley as Chief Business Officer. She has more than 25 years of experience in the biotechnology and bio/pharmaceutical industry. Prior to joining GBI, she held senior commercial development roles at KBI Biopharma, Pfanstiehl, and SAFC (now part of MilliporeSigma). 

Source: GBI Biomanufacturing 

Scinai Biopharma Services Names Head of CDMO Facility 
Scinai Biopharma Services, a CDMO, has appointed Eilon Elmalem, currently a consultant, as Site Head of its facility in Yavne, Israel, effective June 14, 2026. Elmalem has worked with Scinai over the past two years as an external consultant and has supported the company’s CDMO activities and operational development efforts. More recently, he has been involved in the transition and operational integration planning of the Yavne facility.  

Prior to joining Scinai, he held senior leadership roles at Merck, Sigma-Aldrich Millipore, including Vice President of Engineering and Process Development, where he oversaw engineering, manufacturing, R&D, and operational activities across multiple sites in Israel, Europe, and the US. 

Source: Scinai Biopharma